Could creatine support mental health? A dietitian breaks down the evidence.
By Isabelle Statovci | Monthly Blog Contributor, Jenerise | Accredited Practising Dietitian & Clinical and Exercise Scientist
In many countries, May is Mental Health Awareness Month. While mental health is a vast landscape encompassing everything from anxiety to trauma and stress resilience, this article will focus on depression. When depression is diagnosed, the conversation typically centers on two established approaches: medication and therapy. Both have strong evidence behind them, and for many people, they work. But for others, those who don’t respond fully to SSRIs, who find therapy helpful but still struggle, who are looking for additional support alongside treatment, the search continues. In that search, creatine has begun to appear.
This may seem unlikely. Creatine is known primarily as a supplement for athletes, studied extensively for its role in muscle performance and recovery. What does it have to do with mood?
The connection lies in brain metabolism. The brain is an extraordinarily energy-demanding organ, consuming roughly 20 percent of the body’s total energy despite being only 2 percent of body mass. When neurons perform their regulatory functions, managing emotions, consolidating memories, generating the kinds of complex thoughts needed for insight and change they require rapid access to energy. The body has a system for this: the creatine-phosphocreatine system, which can regenerate ATP (the cell’s energy currency) in 5 to 10 seconds (Kreider et al., 2022).
Under conditions of metabolic stress such as chronic sleep deprivation, high cognitive load, depression itself, this system can become strained. Exogenous creatine supplementation raises phosphocreatine stores in the brain, effectively providing a larger energy buffer. Whether this translates to clinical benefit is the question the research is beginning to answer. The answer, so far, is more complex than individual trials might suggest.
When it comes to mental health, the bulk of the clinical trial data we have right now focuses specifically on whether creatine supplementation can improve outcomes in major depression. This clustering stems from neuroenergetics: neuroimaging shows that depressed brains often exhibit distinct cellular energy crises and depleted phosphocreatine levels. Because creatine's primary mechanism is acting as a rapid ATP energy buffer, it provides a clear biochemical rationale for depression that conditions driven by fear-circuitry or neurotransmitter hyper-reactivity, like anxiety or trauma, do not share.
What the Evidence Shows
Multiple randomized controlled trials have found that when creatine is added to existing treatment, whether medication, therapy, or both, it can produce measurable improvements in depressive symptoms (Lyoo et al., 2012; Sherpa et al., 2024; Fares et al., 2026). However, when these findings are pooled together, the picture becomes more complex.
A 2012 trial led by Lyoo and colleagues is among the clearest (Lyoo et al., 2012). Fifty-two women with Major Depressive Disorder (MDD) received escitalopram (an Selective Serotonin Reuptake Inhibitor or SSRI) plus either creatine or placebo over 8 weeks. The creatine dose began at 3 grams daily for the first week, then increased to 5 grams daily. By week 8, the improvement in depression severity was significantly greater in the creatine group compared to placebo. More notably, 52 percent of the creatine group achieved remission of symptoms compared to only 26 percent in the placebo group.
More recent work confirms this pattern in individual trials. A 2024 trial by Sherpa and colleagues examined creatine as an adjunct to cognitive behavioral therapy (CBT) in 100 adults with depression (Sherpa et al., 2024). Those receiving 5 grams of creatine daily alongside CBT showed greater reductions in depressive symptoms over 8 weeks than those receiving CBT plus placebo. The improvement emerged steadily over the treatment period.
Neuroimaging studies add another perspective. When researchers have measured brain metabolism directly using magnetic resonance spectroscopy, they have found that creatine supplementation increases brain phosphocreatine levels and markers of neuronal health (Yoon et al., 2016; Sung et al., 2025). In one study, women receiving creatine alongside an SSRI showed increased prefrontal levels of N-acetylaspartate (a marker of neuronal integrity) and enhanced functional connectivity in brain networks associated with mood regulation (Yoon et al., 2016).
But here is where the complexity emerges: a 2025 systematic review and meta-analysis by Eckert and colleagues examined 11 randomized controlled trials involving 1093 participants (Eckert et al., 2025). When the results were pooled, the standardized mean difference was -0.34, equivalent to approximately 2.2 points on the 17-item Hamilton Depression Rating Scale. This is below the minimal important difference of 3.0 points, meaning the average effect size falls short of what is typically considered clinically meaningful. The GRADE assessment rated the certainty of evidence as very low. Additionally, substantial heterogeneity existed between studies, and subgroup analyses suggested evidence of bias favoring creatine.
This does not mean the trials are wrong or that creatine has no effect. Rather, it means that the promise shown in individual trials appears smaller and less certain when examined collectively. Effects were notably larger in clinically depressed populations specifically, which may indicate that creatine is more likely to help people with diagnosed depression than in mixed or non-depressed samples. But even within that subgroup, the certainty remains low.
What Matters About These Findings
First, the complexity itself is important. Individual randomized controlled trials, particularly the Lyoo and Sherpa studies, do show meaningful improvements. These studies are rigorous and the findings deserve attention. However, the meta-analytic evidence, which combines all available trials, suggests more modest average effects and substantially lower confidence in those effects. This gap between individual trial results and pooled findings is not unusual in psychiatric research and reflects the challenge of comparing across different populations, dosing regimens, durations, and outcome measures.
Second, most studies have been relatively small and of short duration (4 to 8 weeks), with limited longer-term data (Eckert et al., 2025). We do not yet know whether benefits are sustained beyond 8-12 weeks or how they look in larger, more diverse populations.
Third, benefit appears most consistent when creatine is added to an existing treatment, medication or therapy, rather than used alone. This makes biological sense: creatine appears to amplify the effectiveness of other interventions by improving the brain’s capacity to respond, not by replacing those interventions (Fares et al., 2026). This is an important distinction. Creatine is not a standalone antidepressant.
Fourth, the doses used in psychiatric trials (3–5 grams daily) are lower than doses shown effective in other research contexts. This dosing gap is clear when we look at adjacent areas of brain research; for instance, when scientists study creatine's ability to rescue a brain under the acute metabolic stress of sleep deprivation, they utilize a profound single acute dose, equivalent to roughly 20 grams taken once prior to sleep restriction, and find immediate, pronounced improvements in processing speed and mental fatigue (Gordji-Nejad et al., 2024). Whether higher psychiatric doses might produce better clinical outcomes in depression is unknown; the research has not been done systematically.
Fifth, there is genuine uncertainty about individual responsiveness. Not everyone benefits equally. Some studies, particularly in people with treatment-resistant depression, have failed to find significant benefits when creatine is added to ongoing antidepressant therapy (Nemets & Levine, 2013). This suggests that creatine may help some people substantially while offering little to others.
An Important Note If You Have Bipolar Disorder
While creatine shows adjunctive promise for unipolar depression, several studies have reported cases of manic or hypomanic switches in bipolar patients receiving creatine supplementation (Toniolo et al., 2017; Fares et al., 2026). These cases are rare but notable.
What This Means Practically
If you are struggling with depression and considering creatine supplementation, here is what the evidence actually supports:
It is most likely to help if you are already engaged in treatment. This might be medication (an SSRI, for instance), therapy (CBT), or both. Creatine appears to work as an adjunct, a tool that may enhance what treatment is already doing, not as a replacement for it. But understand that the average effect is modest and uncertain.
The evidence is strongest in women with diagnosed depression. Many of the most robust trials included women predominantly or examined sex-based differences. The meta-analysis noted larger effects in clinically depressed populations specifically. Whether this reflects real biological differences in creatine metabolism or other factors is unclear. Either way, the data are clearer in women with diagnosed depression than in other groups.
It takes time. The improvements observed in trials typically emerge over 4 to 8 weeks (Sherpa et al., 2024). This is not a rapid intervention. If you are in acute distress or crisis, your first step should be to speak with a mental health professional, not to begin supplementation.
Standard dosing appears safe. Across studies, doses of 3–5 grams daily have been well tolerated with few adverse effects beyond occasional gastrointestinal discomfort (Paray et al., 2025; Stout et al., 2025; Gil et al., 2025). This is reassuring, though it does not guarantee that every person will tolerate it well.
Other factors remain foundational. Sleep, movement, meaningful connection, and stress management are not optional additions to treatment. They are essential. Creatine might help you respond better to your therapy or medication and support cognitive clarity, but it will not compensate for chronic sleep deprivation or profound social isolation.
Managing Expectations
The emerging field of nutritional psychiatry is built on a straightforward premise: the brain is an organ with metabolic needs, and optimising those needs may matter for mental health. This does not mean depression is simply a nutritional problem. It is a complex condition with genetic, neurobiological, psychological, and social foundations. But it does mean that supporting brain energy metabolism might be one useful strategy among many.
Creatine is one piece of that equation. It supports brain energy metabolism. For some people, particularly those already engaged in treatment for depression, this support appears meaningful. But we should be mindful that it is not a replacement for therapy, medication when indicated, managing sleep and stress, building resilience through movement and connection.
The research on creatine and mental health is still evolving. The biological rationale is sound, the safety profile is reassuring, and some individual trials show meaningful improvements. But the meta-analytic evidence suggests that average effects are modest and certainty is low. This is not a reason to dismiss the research entirely. Rather, it is a reason to approach creatine as an experimental adjunct worth discussing with a clinician, not as an established or proven treatment. Larger, longer, and more rigorous trials are needed before clearer conclusions can be drawn.
If you are considering it, talk with your clinician first. Understand what the current evidence shows: individual studies are promising, but the pooled evidence is more cautious.
Key Takeaways
Individual randomized controlled trials suggest creatine supplementation may enhance the effectiveness of antidepressant medication or cognitive behavioral therapy in some people with depression.
However, a 2025 meta-analysis of 11 trials (1093 participants) found effect sizes below the clinically important threshold, with very low certainty of evidence.
Effects appear larger in clinically depressed populations, but certainty remains low across all groups.
Typical doses (3–5 grams daily) are well tolerated with minimal side effects.
Benefit is most likely when creatine is used as an adjunct to existing treatment, not as a standalone intervention.
If you have bipolar disorder, discuss creatine with your clinician, as isolated cases of mood switching have been reported.
Creatine supports brain energy metabolism but does not replace foundational lifestyle practices; sleep, stress management, movement, and connection remain essential.
We all rise together,
Isabelle
Medical Disclaimer: The information provided in this article is for educational and informational purposes only and does not constitute medical or psychiatric advice. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician, psychiatrist, or other qualified healthcare provider with any questions you may have regarding a medical or mental health condition.
Frequently Asked Questions
Does creatine help with depression?
Some randomised controlled trials suggest creatine may enhance the effectiveness of antidepressant medication or CBT when used as an adjunct. However, a 2025 meta-analysis found the average effect size was below the clinically meaningful threshold, with low certainty of evidence. It is not a standalone treatment.
How much creatine should you take for depression?
Clinical trials have used 3–5 grams daily. This is lower than doses used in some other research contexts. Higher doses for psychiatric purposes have not been systematically studied.
Is creatine safe for mental health use?
At standard doses (3–5g daily), creatine is well tolerated with minimal side effects beyond occasional gastrointestinal discomfort. People with bipolar disorder should consult a clinician before use, as isolated cases of mood switching have been reported.
How long does creatine take to work for depression?
Trials typically observe improvements over 4–8 weeks. It is not a rapid intervention.
Can women benefit more from creatine for depression?
Several of the most robust trials focused on women, and meta-analytic subgroup data suggests effects may be more pronounced in clinically depressed women. Whether this reflects biological differences in creatine metabolism is not yet clear.
References
Eckert I, et al. Creatine supplementation for treating symptoms of depression: a systematic review and meta-analysis. British Journal of Nutrition, 2025.
Fares B, et al. The Effect of Creatine Monohydrate on Mental Disorders: A Systematic Review of Randomized Controlled Trials. Canadian Journal of Psychiatry, 2026.
Gil A, et al. Safety of creatine supplementation: analysis of the frequency of reported side effects in clinical trials. Journal of the International Society of Sports Nutrition, 2025.
Gordji-Nejad A, et al. Single dose creatine improves cognitive performance and induces changes in cerebral high energy phosphates during sleep deprivation. Scientific Reports, 2024.
Kreider R, et al. Bioavailability, efficacy, safety, and regulatory status of creatine and related compounds: a critical review. Nutrients, 2022.
Lyoo I, et al. A randomized, double-blind placebo-controlled trial of oral creatine monohydrate augmentation for enhanced response to a selective serotonin reupdate inhibitor in women with major depressive disorder. The American Journal of Psychiatry, 2012.
Nemets B, et al. A pilot dose-finding clinical trial of creatine monohydrate augmentation to SSRIs/SNRIs/NASA antidepressant treatment in major depression. International Clinical Psychopharmacology, 2013.
Paray A, et al. Fueling strength and recovery: basics of creatine monohydrate, usage, benefits, effectiveness and misconceptions. International Journal of Research and Review, 2025.
Sherpa N, et al. Efficacy and safety profile of oral creatine monohydrate in add-on to cognitive-behavioural therapy in depression: An 8-week pilot, double-blind, randomised, placebo-controlled feasibility and exploratory trial in an under-resourced area. European Neuropsychopharmacology, 2024.
Stout J, et al. The birth of modern sports nutrition: tracing the path from muscle biopsies to creatine supplementation—a narrative review. Journal of the International Society of Sports Nutrition, 2025.
Sung Y, et al. Metabolite Maps Exhibit Add-on Effects of Creatine Monohydrate on Brain ATP in Depressed Subjects. ISMRM Annual Meeting, 2025.
Toniolo R, et al. A randomized, double-blind, placebo-controlled, proof-of-concept trial of creatine monohydrate as adjunctive treatment for bipolar depression. Journal of Neural Transmission, 2017.
Yoon S, et al. Effects of Creatine Monohydrate Augmentation on Brain Metabolic and Network Outcome Measures in Women With Major Depressive Disorder. Biological Psychiatry, 2016.
